Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shugan Jieyu is a standardized Traditional Chinese Medicine (TCM) formulation primarily indicated for the treatment of mild to moderate depression. It is a botanical combination product consisting of two main active herbal extracts: *Hypericum perforatum* (St. John's Wort) and *Acanthopanax senticosus* (Siberian Ginseng). The therapeutic efficacy of Shugan Jieyu is attributed to the synergistic effects of its components, particularly the reuptake inhibition of monoamine neurotransmitters such as serotonin, norepinephrine, and dopamine by St. John's Wort, combined with the adaptogenic and neuroprotective properties of *Acanthopanax senticosus*. Developed and manufactured by Lunan Hope Pharmaceutical, it has been extensively studied in clinical trials as an alternative or adjunct to conventional selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, demonstrating comparable efficacy with a potentially more favorable safety profile regarding side effects like sexual dysfunction and weight gain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shugan jieyu (Lunan Houpu Pharmaceutical Co., Ltd.).